{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T11:56:00Z","timestamp":1792410960092,"version":"4.4.0"},"reference-count":87,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T00:00:00Z","timestamp":1555372800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2019.00751","type":"journal-article","created":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T05:06:26Z","timestamp":1555391186000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":160,"title":["The Development of a Vaccine Against Meningococcus B Using Reverse Vaccinology"],"prefix":"10.3389","volume":"10","author":[{"given":"Vega","family":"Masignani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariagrazia","family":"Pizza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Richard","family":"Moxon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,4,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1093\/infdis\/126.5.514","article-title":"Immunologic response of man to group B meningococcal polysaccharide vaccines","volume":"126","author":"Wyle","year":"1972","journal-title":"J Infect Dis"},{"key":"B2","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.4049\/jimmunol.127.3.1011","article-title":"Immunochemistry of groups A, B, and C meningococcal polysaccharide-tetanus toxoid conjugates","volume":"127","author":"Jennings","year":"1981","journal-title":"J Immunol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1056\/NEJM197002192820803","article-title":"Prevention of meningococcal disease by group C polysaccharide vaccine","volume":"282","author":"Artenstein","year":"1970","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1056\/NEJM197709292971302","article-title":"Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age","volume":"297","author":"Peltola","year":"1977","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"crossref","first-page":"4402","DOI":"10.4049\/jimmunol.138.12.4402","article-title":"An IgG monoclonal antibody to group B meningococci cross-reacts with developmentally regulated polysialic acid units of glycoproteins in neural and extraneural tissues","volume":"138","author":"Finne","year":"1987","journal-title":"J Immunol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/S0140-6736(83)90340-9","article-title":"Antigenic similarities between brain components and bacteria causing meningitis","volume":"2","author":"Finne","year":"1983","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/0896-6273(93)90228-J","article-title":"Genetic deletion of a neural cell adhesion molecule variant (N-CAM-180) produces distinct defects in the central nervous system","volume":"11","author":"Tomasiewicz","year":"1993","journal-title":"Neuron"},{"key":"B8","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1002\/jnr.490130109","article-title":"Influences of the neural cell adhesion molecule on axon growth and guidance","volume":"13","author":"Rutishauser","year":"1985","journal-title":"J Neurosci Res"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1084\/jem.165.4.1207","article-title":"N-propionylated group B meningococcal polysaccharide mimics a unique epitope on group B Neisseria meningitidis","volume":"165","author":"Jennings","year":"1987","journal-title":"J Exp Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/j.vaccine.2003.10.005","article-title":"Clinical evaluation of a group B meningococcal N-propionylated polysaccharide conjugate vaccine in adult, male volunteers","volume":"22","author":"Bruge","year":"2004","journal-title":"Vaccine"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e117","DOI":"10.1093\/cid\/cir500","article-title":"Comparative long-term adverse effects elicited by invasive group B and C meningococcal infections","volume":"53","author":"Gottfredsson","year":"2011","journal-title":"Clin Infect Dis"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1084\/jem.129.6.1327","article-title":"Human immunity to the meningococcus","volume":"129","author":"Goldschneider","year":"1969","journal-title":"J Exp Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1084\/jem.129.6.1307","article-title":"Human immunity to the meningococcus","volume":"129","author":"Goldschneider","year":"1969","journal-title":"J Exp Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.4161\/hv.24129","article-title":"Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV): lessons from past programs and implications for the future","volume":"9","author":"Holst","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1097\/00006454-200111000-00010","article-title":"Immunogenicity of a serogroup B meningococcal vaccine against multiple Neisseria meningitidis strains in infants","volume":"20","author":"Morley","year":"2001","journal-title":"Pediatr Infect Dis J"},{"key":"B16","doi-asserted-by":"publisher","first-page":"S54","DOI":"10.1086\/648966","volume":"50","author":"Granoff","year":"2010","journal-title":"Clin Infect Dis"},{"key":"B17","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1111\/j.1574-695X.2000.tb01494.x","article-title":"Identification and characterisation of a novel conserved outer membrane protein from Neisseria meningitidis","volume":"28","author":"Peak","year":"2000","journal-title":"FEMS Immunol Med Microbiol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e72003","DOI":"10.1371\/journal.pone.0072003","article-title":"Evaluation of truncated NhhA protein as a candidate meningococcal vaccine antigen","volume":"8","author":"Peak","year":"2013","journal-title":"PLoS ONE"},{"key":"B19","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1385\/1-59259-148-5:81","article-title":"Outer membrane protein vesicle vaccines for meningococcal disease","volume":"66","author":"Frasch","year":"2001","journal-title":"Methods Mol Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1093\/aje\/kwm147","article-title":"A prospective study of the effectiveness of the New Zealand meningococcal B vaccine","volume":"166","author":"Kelly","year":"2007","journal-title":"Am J Epidemiol"},{"key":"B21","first-page":"125","article-title":"Results of an efficacy trial with an outer membrane vesicle vaccine against systemic serogroup B meningococcal disease in Norway","volume":"14","author":"Bjune","year":"1991","journal-title":"NIPH Ann"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1093\/ije\/24.5.1050","article-title":"Assessment of the direct effectiveness of BC meningococcal vaccine in Rio de Janeiro, Brazil: a case-control study","volume":"24","author":"Noronha","year":"1995","journal-title":"Int J Epidemiol"},{"key":"B23","first-page":"67","article-title":"Production, characterization and control of MenB-vaccine \u201cFolkehelsa\u201d: an outer membrane vesicle vaccine against group B meningococcal disease","volume":"14","author":"Fredriksen","year":"1991","journal-title":"NIPH Ann"},{"key":"B24","first-page":"195","article-title":"Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba","volume":"14","author":"Sierra","year":"1991","journal-title":"NIPH Ann"},{"key":"B25","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/0264-410X(94)00037-N","article-title":"Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Chilean National Committee for Meningococcal Disease","volume":"13","author":"Boslego","year":"1995","journal-title":"Vaccine"},{"key":"B26","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1016\/j.vaccine.2005.01.063","article-title":"MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain","volume":"23","author":"Oster","year":"2005","journal-title":"Vaccine"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1016\/j.vaccine.2005.09.043","article-title":"Safety and immunogenicity of New Zealand strain meningococcal serogroup B OMV vaccine in healthy adults: beginning of epidemic control","volume":"24","author":"Thornton","year":"2006","journal-title":"Vaccine"},{"key":"B28","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1016\/S0264-410X(99)00044-4","article-title":"Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins","volume":"17","author":"Cartwright","year":"1999","journal-title":"Vaccine"},{"key":"B29","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1126\/science.7542800","article-title":"Whole-genome random sequencing and assembly of Haemophilus influenzae Rd","volume":"269","author":"Fleischmann","year":"1995","journal-title":"Science"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/S0140-6736(97)03259-5","article-title":"Applications of molecular microbiology to vaccinology","volume":"350","author":"Moxon","year":"1997","journal-title":"Lancet"},{"key":"B31","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/S0140-6736(86)90124-8","article-title":"An outbreak of meningococcal disease in Gloucestershire","volume":"2","author":"Cartwright","year":"1986","journal-title":"Lancet"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1126\/science.287.5459.1816","article-title":"Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing","volume":"287","author":"Pizza","year":"2000","journal-title":"Science"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1126\/science.287.5459.1809","article-title":"Complete genome sequence of Neisseria meningitidis serogroup B strain MC58","volume":"287","author":"Tettelin","year":"2000","journal-title":"Science"},{"key":"B34","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/S1369-5274(00)00119-3","article-title":"Reverse vaccinology","volume":"3","author":"Rappuoli","year":"2000","journal-title":"Curr Opin Microbiol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1084\/jem.20021911","article-title":"Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA 1870","volume":"197","author":"Masignani","year":"2003","journal-title":"J Exp Med"},{"key":"B36","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1046\/j.1365-2958.2000.02000.x","article-title":"Repeat-associated phase variable genes in the complete genome sequence of Neisseria meningitidis strain MC58","volume":"37","author":"Saunders","year":"2000","journal-title":"Mol Microbiol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1038\/nature07769","article-title":"Neisseria meningitidis recruits factor H using protein mimicry of host carbohydrates","volume":"458","author":"Schneider","year":"2009","journal-title":"Nature"},{"key":"B38","doi-asserted-by":"publisher","first-page":"41767","DOI":"10.1074\/jbc.M111.289314","article-title":"Structure of the C-terminal domain of Neisseria Heparin Binding Antigen (NHBA), one of the main antigens of a novel vaccine against Neisseria meningitidis","volume":"286","author":"Esposito","year":"2011","journal-title":"J Biol Chem"},{"key":"B39","doi-asserted-by":"publisher","first-page":"e0201922","DOI":"10.1371\/journal.pone.0201922","article-title":"Structures of NHBA elucidate a broadly conserved epitope identified by a vaccine induced antibody","volume":"13","author":"Maritan","year":"2018","journal-title":"PLoS ONE"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.01914-18","article-title":"NadA3 structures reveal undecad coiled coils and LOX1 binding regions competed by meningococcus B vaccine-elicited human antibodies","author":"Liguori","year":"2018","journal-title":"MBio"},{"key":"B41","doi-asserted-by":"publisher","first-page":"17128","DOI":"10.1073\/pnas.1419686111","article-title":"Structure of the meningococcal vaccine antigen NadA and epitope mapping of a bactericidal antibody","volume":"111","author":"Malito","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"B42","doi-asserted-by":"publisher","first-page":"3770","DOI":"10.1073\/pnas.0915162107","article-title":"Neisseria meningitidis GNA2132, a heparin-binding protein that induces protective immunity in humans","volume":"107","author":"Serruto","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"B43","doi-asserted-by":"publisher","first-page":"e0162878","DOI":"10.1371\/journal.pone.0162878","article-title":"Neisserial Heparin Binding Antigen (NHBA) contributes to the adhesion of Neisseria meningitidis to human epithelial cells","volume":"11","author":"Vacca","year":"2016","journal-title":"PLoS ONE"},{"key":"B44","doi-asserted-by":"publisher","first-page":"e0194662","DOI":"10.1371\/journal.pone.0194662","article-title":"Neisseria Heparin Binding Antigen is targeted by the human alternative pathway C3-convertase","volume":"13","author":"Di Fede","year":"2018","journal-title":"PLoS ONE"},{"key":"B45","doi-asserted-by":"publisher","first-page":"8738","DOI":"10.1074\/jbc.M808831200","article-title":"Structural basis for the immunogenic properties of the meningococcal vaccine candidate LP 2086","volume":"284","author":"Mascioni","year":"2009","journal-title":"J Biol Chem"},{"key":"B46","doi-asserted-by":"publisher","first-page":"2714","DOI":"10.1073\/pnas.1521142113","article-title":"Expression of factor H binding protein in meningococcal strains can vary at least 15-fold and is genetically determined","volume":"113","author":"Biagini","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"key":"B47","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1586\/14760584.2015.1016915","article-title":"Neisseria meningitidis factor H-binding protein fHbp: a key virulence factor and vaccine antigen","volume":"14","author":"Seib","year":"2015","journal-title":"Expert Rev Vaccines"},{"key":"B48","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1111\/j.1365-2958.2004.04423.x","article-title":"Neisseria meningitidis NadA is a new invasin which promotes bacterial adhesion to and penetration into human epithelial cells","volume":"55","author":"Capecchi","year":"2005","journal-title":"Mol Microbiol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1084\/jem.20020407","article-title":"NadA, a novel vaccine candidate of Neisseria meningitidis","volume":"195","author":"Comanducci","year":"2002","journal-title":"J Exp Med"},{"key":"B50","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1128\/CVI.00825-13","article-title":"Neisseria adhesin A variation and revised nomenclature scheme","volume":"21","author":"Bambini","year":"2014","journal-title":"Clin Vaccine Immunol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1128\/IAI.01085-12","article-title":"Transcriptional regulation of the nadA gene in Neisseria meningitidis impacts the prediction of coverage of a multicomponent meningococcal serogroup B vaccine","volume":"81","author":"Fagnocchi","year":"2013","journal-title":"Infect Immun"},{"key":"B52","doi-asserted-by":"publisher","first-page":"10834","DOI":"10.1073\/pnas.0603940103","article-title":"A universal vaccine for serogroup B meningococcus","volume":"103","author":"Giuliani","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"B53","doi-asserted-by":"publisher","first-page":"646","DOI":"10.4161\/hv.7.6.15482","article-title":"The first use of an investigational multicomponent meningococcal serogroup B vaccine (4CMenB) in humans","volume":"7","author":"Toneatto","year":"2011","journal-title":"Hum Vaccin"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1086\/656741","article-title":"Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy","volume":"51","author":"Findlow","year":"2010","journal-title":"Clin Infect Dis"},{"key":"B55","doi-asserted-by":"publisher","first-page":"e71","DOI":"10.1097\/INF.0b013e3181f59f6d","article-title":"Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial","volume":"29","author":"Snape","year":"2010","journal-title":"Pediatr Infect Dis J"},{"key":"B56","doi-asserted-by":"publisher","first-page":"2775","DOI":"10.1016\/S0140-6736(16)31921-3","article-title":"Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: a national observational cohort study","volume":"388","author":"Parikh","year":"2016","journal-title":"Lancet"},{"key":"B57","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/S0140-6736(12)61961-8","article-title":"Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials","volume":"381","author":"Vesikari","year":"2013","journal-title":"Lancet"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1136\/archdischild-2017-312941","article-title":"An increase in accident and emergency presentations for adverse events following immunisation after introduction of the group B meningococcal vaccine: an observational study","author":"Nainani","year":"2017","journal-title":"Arch Dis Child."},{"key":"B59","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S2352-4642(18)30103-2","article-title":"Safety of multicomponent meningococcal group B vaccine (4CMenB) in routine infant immunisation in the UK: a prospective surveillance study","volume":"2","author":"Bryan","year":"2018","journal-title":"Lancet Child Adolesc Health"},{"key":"B60","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/S1473-3099(13)70006-9","article-title":"Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment","volume":"13","author":"Vogel","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"B61","doi-asserted-by":"publisher","first-page":"19490","DOI":"10.1073\/pnas.1013758107","article-title":"Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines","volume":"107","author":"Donnelly","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"B62","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.vaccine.2013.03.063","article-title":"Diversity of Canadian meningococcal serogroup B isolates and estimated coverage by an investigational meningococcal serogroup B vaccine (4CMenB)","volume":"32","author":"Bettinger","year":"2013","journal-title":"Vaccine"},{"key":"B63","doi-asserted-by":"publisher","first-page":"e0176177","DOI":"10.1371\/journal.pone.0176177","article-title":"Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Portugal","volume":"12","author":"Sim\u00f5es","year":"2017","journal-title":"PLoS ONE"},{"key":"B64","doi-asserted-by":"publisher","first-page":"e0150721","DOI":"10.1371\/journal.pone.0150721","article-title":"Predicted strain coverage of a new meningococcal multicomponent vaccine (4CMenB) in Spain: analysis of the differences with other European countries","volume":"11","author":"Abad","year":"2016","journal-title":"PLoS ONE"},{"key":"B65","first-page":"103","article-title":"Predicted strain coverage of a new protein-based meningococcal vaccine in the Czech Republic","volume":"63","author":"Kr\u00ed\u017dov\u00e1","year":"2014","journal-title":"Epidemiol Mikrobiol Imunol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.1016\/j.vaccine.2015.04.015","article-title":"MATS: global coverage estimates for 4CMenB, a novel multicomponent meningococcal B vaccine","volume":"33","author":"Medini","year":"2015","journal-title":"Vaccine"},{"key":"B67","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.vaccine.2015.11.070","article-title":"High predicted strain coverage by the multicomponent meningococcal serogroup B vaccine (4CMenB) in Poland","volume":"34","author":"Wa\u015bko","year":"2016","journal-title":"Vaccine"},{"key":"B68","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/1471-2180-14-111","article-title":"Diversity of Greek meningococcal serogroup B isolates and estimated coverage of the 4CMenB meningococcal vaccine","volume":"14","author":"Tzanakaki","year":"2014","journal-title":"BMC Microbiol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"e00261","DOI":"10.1128\/mSphere.00261-17","article-title":"Meningococcal Antigen Typing System (MATS)-based Neisseria meningitidis serogroup B coverage prediction for the MenB-4C vaccine in the United States","volume":"2","author":"Rajam","year":"2017","journal-title":"mSphere"},{"key":"B70","doi-asserted-by":"publisher","first-page":"4968","DOI":"10.1016\/j.vaccine.2013.08.006","article-title":"Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage","volume":"31","author":"Frosi","year":"2013","journal-title":"Vaccine"},{"key":"B71","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1128\/CVI.00669-14","article-title":"A large portion of meningococcal antigen typing system-negative meningococcal strains from spain is killed by sera from adolescents and infants immunized with 4CMenB","volume":"22","author":"Abad","year":"2015","journal-title":"Clin Vaccine Immunol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1093\/cid\/cix154","article-title":"Impact of an immunization campaign to control an increased incidence of serogroup B meningococcal disease in one region of Quebec, Canada","volume":"64","author":"De Wals","year":"2017","journal-title":"Clin Infect Dis"},{"key":"B73","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1056\/NEJMoa1514866","article-title":"Meningococcal B vaccine during a university outbreak","volume":"375","author":"Basta","year":"2016","journal-title":"N Engl J Med"},{"key":"B74","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s11908-017-0587-4","article-title":"Serogroup B meningococcus outbreaks, prevalence, and the case for standard vaccination","volume":"19","author":"Grogan","year":"2017","journal-title":"Curr Infect Dis Rep"},{"key":"B75","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1586\/14760584.2014.944902","article-title":"Shortcomings of pertussis vaccines: why we need a third generation vaccine","volume":"13","author":"Poolman","year":"2014","journal-title":"Expert Rev Vaccines"},{"key":"B76","doi-asserted-by":"publisher","first-page":"e01074","DOI":"10.1128\/mBio.01074-14","article-title":"Global population structure and evolution of Bordetella pertussis and their relationship with vaccination","volume":"5","author":"Bart","year":"2014","journal-title":"MBio"},{"key":"B77","doi-asserted-by":"publisher","first-page":"e00163","DOI":"10.1128\/mBio.00163-13","article-title":"Conservation of meningococcal antigens in the genus Neisseria","volume":"4","author":"Muzzi","year":"2013","journal-title":"MBio"},{"key":"B78","doi-asserted-by":"publisher","first-page":"4690","DOI":"10.1016\/j.vaccine.2016.08.015","article-title":"Distribution of Bexsero(R) Antigen Sequence Types (BASTs) in invasive meningococcal disease isolates: implications for immunisation","volume":"34","author":"Brehony","year":"2016","journal-title":"Vaccine"},{"key":"B79","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1056\/NEJM200105033441807","article-title":"Meningococcal disease","volume":"344","author":"Rosenstein","year":"2001","journal-title":"N Engl J Med"},{"key":"B80","year":"2010","journal-title":"Immunization, VaB Meningococcal Disease"},{"key":"B81","doi-asserted-by":"publisher","first-page":"S58","DOI":"10.1016\/S0264-410X(01)00299-7","article-title":"Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story","volume":"20","author":"Miller","year":"2001","journal-title":"Vaccine"},{"key":"B82","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1136\/bmj.326.7385.365","article-title":"Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis","volume":"326","author":"Ramsay","year":"2003","journal-title":"BMJ"},{"key":"B83","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1016\/S0140-6736(14)60842-4","article-title":"Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial","volume":"384","author":"Read","year":"2014","journal-title":"Lancet"},{"key":"B84","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1093\/ije\/22.4.742","article-title":"Estimation of vaccine effectiveness using the screening method","volume":"22","author":"Farrington","year":"1993","journal-title":"Int J Epidemiol"},{"key":"B85","unstructured":"Surveillance of Invasive Bacterial Diseases in Europe 20072010"},{"key":"B86","year":"2017","journal-title":"Invasive Meningococcal Disease in England: Annual Laboratory Confirmed Reports for Epidemiological Year 2016 to 2017"},{"key":"B87","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1099\/jmm.0.46288-0","article-title":"Epidemiology of meningococcal disease in England and Wales 1993\/94 to 2003\/04: contribution and experiences of the Meningococcal Reference Unit","volume":"55","author":"Gray","year":"2006","journal-title":"J Med Microbiol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.00751\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T19:44:35Z","timestamp":1694807075000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.00751\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,16]]},"references-count":87,"alternative-id":["10.3389\/fimmu.2019.00751"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2019.00751","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,16]]},"article-number":"751"}}